Journals / Bezmiâlem Science / 2020 / Cilt: 8 - Sayı: 3

Promising Potential Pharmaceuticals from the GenusCordyceps for COVID-19 Treatment: A Review Study

COVİD-19 Tedavisi için Cordysceps Cinsinden Gelen Potansiyel İlaçlar: Bir Derleme Çalışması

Pages
85–89
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Thisreview aims to discuss whether C. sinensis and C. militaris can beused for COVID-19 treatment in light of previous studies.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:A novel coronavirus (2019-nCoV), named as severe acuterespiratory syndrome-CoV-2 (SARS-CoV-2) later, was first detectedat Wuhan, China, in December 2019.
📊
Key Findings & Data:COVID-19, the diseasecaused by SARS-CoV-2, is highly contagious and has mild to severesymptoms ranging from generalized weakness, headache, dizziness,fever, cough, and dyspnea to severe hypoxia with acute respiratorydistress syndrome and multiorgan failure.
💡
Conclusion & Impact:Thisreview aims to discuss whether C. sinensis and C. militaris can beused for COVID-19 treatment in light of previous studies.
🔬Design:Review & Systematic Survey
📍Scope:2019 Verileri
⚙️Variables:Domain Parameters

Abstract

A novel coronavirus (2019-nCoV), named as severe acuterespiratory syndrome-CoV-2 (SARS-CoV-2) later, was first detectedat Wuhan, China, in December 2019. COVID-19, the diseasecaused by SARS-CoV-2, is highly contagious and has mild to severesymptoms ranging from generalized weakness, headache, dizziness,fever, cough, and dyspnea to severe hypoxia with acute respiratorydistress syndrome and multiorgan failure. The unclarity of the virus’pathophysiology and lack of a targeted therapy make the disease verychallenging to treat for physicians. Cordyceps sinensis and Cordycepsmilitaris are entomopathogenic fungi which are used for their anti inflammatory, immunomodulatory, lung improving, and antiviralfunctions in Traditional Chinese Medicine. Thus, advanced searchfor C. sinensis and C. militaris has proven several compounds fromthese fungi have the functions that they are thought to have. Thisreview aims to discuss whether C. sinensis and C. militaris can beused for COVID-19 treatment in light of previous studies.

Özet

Şiddetli akut solunum yolu enfeksiyonu-koronavirüs-2 (SARSCoV-2) olarak adlandırılan yeni bir koronavirüs (2019-nCoV), ilk olarak Aralık 2019’da Vuhan, Çin’de tespit edildi. SARS-CoV-2’nin neden olduğu COVID-19 oldukça bulaşıcıdır ve genel halsizlik, baş ağrısı, baş dönmesi, ateş, öksürük ve nefes darlığından akut solunum sıkıntısı sendromu ve multiorgan yetmezliği olan şiddetli hipoksiye kadar hafif ile şiddetli semptomlara sahiptir. Virüsün patofizyolojisinin belirsizliği ve hedefe yönelik bir tedavinin olmaması, doktorlar için hastalığı tedavi etmeyi çok zorlaştırır. Cordyceps sinensis ve Cordyceps militaris, Geleneksel Çin Tıbbında anti-enflamatuvar, immünomodülatör, akciğer iyileştirici ve antiviral fonksiyonları için kullanılan entomopatojenik mantarlardır. Bu nedenle, C. sinensis ve C. militaris için yapılan ileri araştırmalar, bu mantarlardan elde edilen çeşitli bileşiklerin düşünülen işlevlere sahip olduklarını kanıtlamıştır. Bu derleme, daha önce yapılan çalışmalar ışığında, C. sinensis ve C. militaris’in COVID-19 tedavisi için kullanılıp kullanılamayacağını tartışmayı amaçlamaktadır.

🔖

Cite This Article

GÜLER, E. M., KAYMAKÇI, M. A. (2022). Promising Potential Pharmaceuticals from the GenusCordyceps for COVID-19 Treatment: A Review Study. Bezmiâlem Science, Cilt: 8 - Sayı: 3, 85–89. https://ajindex.com/articles/464094

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Richman DD, Whitley RJ, Hayden FG. Clinical virology. 4th ed. Hoboken, NJ; John Wiley & Sons: 2016
  2. Seah I, Agrawal R. Can the coronavirus disease 2019 (COVID-19) affect the eyes? A review of coronaviruses and ocular implications in humans and animals. Ocul Immunol Inflamm 2020;28:391-5
  3. Bai Y, Yao L, Wei T, Tian F, Jin D-Y, Chen L, et al. Presumed asymptomatic carrier transmission of COVID-19. JAMA 2020;323:1406-7
  4. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020;382:727-33. 5. de Groot RJ, Baker SC, Baric RS, Brown CS, Drosten C, Enjuanes L, et al. Commentary: Middle East respiratory syndrome coronavirus (MERS-CoV): announcement of the Coronavirus Study Group. J Virol 2013;87:7790-2
  5. Wevers BA, van der Hoek L. Recently discovered human coronaviruses. Clin Lab Med 2009;29:715-24
  6. Yuki K, Fujiogi M, Koutsogiannaki S. COVID-19 pathophysiology: A review. Clin Immunol 2020:108427
  7. Gorbalenya AE. Severe acute respiratory syndrome-related coronavirus–The species and its viruses, a statement of the Coronavirus Study Group. BioRxiv. 2020
  8. Sohrabi C, Alsafi Z, O’Neill N, Khan M, Kerwan A, Al-Jabir A, et al. World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19). Int J Surg 2020;76:71-6
  9. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497-506
  10. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020;395:507-13
  11. Mahallawi WH, Khabour OF, Zhang Q, Makhdoum HM, Suliman BA. MERS-CoV infection in humans is associated with a proinflammatory Th1 and Th17 cytokine profile. Cytokine 2018;104:8-13
  12. Wong C, Lam C, Wu A, Ip W, Lee N, Chan I, et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin Exper Immunol 2004;136:95-103
  13. Zhou Y, Fu B, Zheng X, Wang D, Zhao C. Pathogenic T cells and inflammatory monocytes incite inflammatory storm in severe COVID-19 patients. Natl Sci Rev 2020:nwaa041.Yang Y, Peng F, Wang R, Guan K, Jiang T, Xu G, et al. The deadly coronaviruses: The 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China. J Autoimmun 2020:102434
  14. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A trial